Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

.2017 Sep 6;25(9):2093-2103.
doi: 10.1016/j.ymthe.2017.07.003. Epub 2017 Jul 8.

RIG-I Activation Protects and Rescues from Lethal Influenza Virus Infection and Bacterial Superinfection

Affiliations

RIG-I Activation Protects and Rescues from Lethal Influenza Virus Infection and Bacterial Superinfection

Christoph Coch et al. Mol Ther..

Abstract

Influenza A virus infection causes substantial morbidity and mortality in seasonal epidemic outbreaks, and more efficient treatments are urgently needed. Innate immune sensing of viral nucleic acids stimulates antiviral immunity, including cell-autonomous antiviral defense mechanisms that restrict viral replication. RNA oligonucleotide ligands that potently activate the cytoplasmic helicase retinoic-acid-inducible gene I (RIG-I) are promising candidates for the development of new antiviral therapies. Here, we demonstrate in an Mx1-expressing mouse model of influenza A virus infection that a single intravenous injection of low-dose RIG-I ligand 5'-triphosphate RNA (3pRNA) completely protected mice from a lethal challenge with influenza A virus for at least 7 days. Furthermore, systemic administration of 3pRNA rescued mice with pre-established fulminant influenza infection and prevented the fatal effects of a streptococcal superinfection. Type I interferon, but not interferon-λ, was required for the therapeutic effect. Our results suggest that the use of RIG-I activating oligonucleotide ligands has the clinical potential to confine influenza epidemics when a strain-specific vaccine is not yet available and to reduce lethality of influenza in severely infected patients.

Keywords: 5’ triphosphate RNA; RIG-I; antivirals; immunostimulatory oligonucleotides; immunotherapy; influenza virus; innate immunity; negative strand RNA virus; type I interferon; type III interferon.

Copyright © 2017. Published by Elsevier Inc.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Systemic 3pRNA Induces CXCL10 in the Lungs and Ameliorates the Course of Non-lethal Influenza Virus Infection (A) C57BL/6 mice were i.v. injected with 25 μg of 3pRNA or the control RNA polycytidylic, polyadenylic acid (polyCA). After 6 hr, expression of CXCL10 in lung tissue was analyzed by qPCR (n = 3 mice). Result shows mean with SD. (B) Left panel shows the experimental setup. Right panel shows that C57BL/6 mice were i.v. injected with 25 μg of 3pRNA or the control RNA polyCA 6 hr before intranasal infection with a non-lethal dose (105 PFU) A/PR/8/34. Body weight of mice was monitored daily. Results show the means and SD of n = 6 mice (ANOVA day 6: PR8 only versus PR8 + control [ctrl] RNA, not significant; PR8 only versus PR8 + 3pRNA, p < 0.01; PR8 + ctrl RNA versus PR8 + 3pRNA, p < 0.05).
Figure 2
Figure 2
Prophylactic Treatment with 3pRNA Leads to Long-Term Protection of Mice against a Lethal Challenge with Influenza Virus B6.A2G-Mx1 mice received a single i.v. injection of 12.5 μg of 3pRNA at 1, 3, or 7 days before they were challenged with a lethal dose of 103 PFU of hvPR/8, a highly virulent variant of A/PR/8/34 (n = 8; untreated: n = 5). (A–C) Body weight (A), survival (B) (log-rank [Mantel-Cox] test: control [ctrl]-RNA versus PR/8 + 3pRNA day −3, p < 0.0001; ctrl-RNA versus PR/8 + 3pRNA day −7, p < 0.0009; PR/8 + 3pRNA day −7 versus PR/8 + 3pRNA day −3, p < 0.32), and clinical score (C) were monitored. (D and E) Mice received repeated i.v. injections of 3pRNA or control RNA on days 7, 5, 3, and 1 before they were challenged with a lethal dose of 103 PFU of hvPR/8. (D and E) Body weight (D) and clinical score (E) were measured (n = 8; ctrl-RNA: n = 3). Results are presented as mean values. Error bars represent the SD.
Figure 3
Figure 3
Therapeutic Administration of 3pRNA Rescues Mice from a Pre-established Lethal Influenza Virus Infection (A) Experimental setup: i.v. 3pRNA treatment at 18 or 30 hr after challenge with influenza virus. (B) B6.A2G-Mx1 mice were infected with 103 PFU of hvPR/8. 18 hr later, 3pRNA or control RNA was injected i.v. (both at 25 μg). Viral RNA was analyzed in lung tissue at day 5 postinfection (n = 4 mice). (C) B6.A2G-Mx1 mice were treated as in (B). Body weight (n = 6 mice; untreated: n = 2), survival (n = 6 mice; untreated: n = 2), and clinical score (n = 5 mice; PR8+3pRNA: n = 3; untreated: n = 2) are depicted (log-rank [Mantel-Cox test]: PR/8 only versus PR/8 + control [ctrl]-RNA, p = 0.65; PR/8 only versus PR/8 + 3pRNA, p = 0.0016; PR/8 + ctrl-RNA versus PR/8 + 3pRNA, p = 0.0015). (D) Mice were treated as in (B) except that 3pRNA was used at a dose of 12.5 and 6.25 μg per injection (means of n = 10 mice; PR/8 without treatment, n = 5 [log-rank (Mantel-Cox) test: PR/8 + ctrl-RNA versus PR/8 + 6.25 3pRNA, p = 0.03; PR/8 + ctrl-RNA versus PR/8 + 12.5 3pRNA, p = 0.03; PR/8 + 12.5 3pRNA versus PR/8 + 6.25 3pRNA, p = 1]). (E) Done as in (C), but chemically synthesized 3pRNA was used (n = 5). (F) Mice were treated as in (B) except injection of 3pRNA was at 30 hr postinfection (log-rank [Mantel-Cox] test: PR/8 only versus PR/8 + ctrl-RNA, p = 0.66; PR/8 only versus PR/8 + 3pRNA, p = 0.0005; PR/8 + ctrl-RNA versus PR/8 + 3pRNA, p = 0.0002). Results are presented as mean values. Error bars represent the SD.
Figure 4
Figure 4
Rescue from Lethal Influenza Virus Infection by Therapeutic Administration of 3pRNA Requires the Type I Interferon Receptor but Is Independent of Interferon-λ (A–D) B6.A2G-Mx1 mice (A) (n = 8, p = 0.0003), B6.A2G-Mx1-Ifnlr1−/− mice lacking functional interferon-λ receptors (B) (n = 6, p = 0.0009), B6.A2G-Mx1-Ifnar1−/− mice lacking functional type I interferon receptors (C) (n = 8, p = 0.35), or B6.A2G-Mx1-Ifnar1−/−Ifnlr1−/− double-knockout mice lacking receptors for both interferon types (D) (n = 8, p = 1.00) were infected with 103 PFU hvPR/8. After 18 hr, mice were i.v. injected with 12.5 μg of 3pRNA or the control RNA polyCA. Body weight and survival were monitored. Results are presented as mean values. Error bars represent the SD. Log-rank (Mantel-Cox) test was used.
Figure 5
Figure 5
Comparison of 3pRNA with Established Oligonucleotide Ligands of TLR7/8 and TLR9 B6.A2G-Mx1 mice were infected with 103 PFU of hvPR/8. 18 hr later, mice were i.v. injected with 3pRNA or the control RNA polyCA (both delivered with jetPEI), i.v. injected with the TLR7/8 ligand 9.2s RNA (delivered with DOTAP), or i.p. injected with CpG1826 (all 12.5 μg per injection). Infected mice without treatment served as control (PR/8 only). (A) At 6 hr after treatment, levels of CXCL10 were analyzed in serum of mice by ELISA (ANOVA: 3pRNA versus negative control [ctrl], p < 0.01; 3pRNA versus 9.2 s, p < 0.05; 9.2 s versus negative ctrl, p < 0.05). (B–D) Body weight (B), survival (log-rank [Mantel-Cox] test: PR/8 + ctrl-RNA versus PR/8 + 3pRNA, p = 0.0016; PR/8 + ctrl-RNA versus PR/8 + 9.2s RNA, p = 0.065; PR/8 + 3pRNA versus PR/8 + 9.2s RNA, p = 0.0019) (C), and clinical score (D) were monitored daily. Results show means of n = 4 or n = 5 animals and n = 2 for PR/8 only. Results are presented as survival curve or mean values with SD.
Figure 6
Figure 6
Therapeutic Administration of 3pRNA Improves the Outcome of Influenza-Infected Mice Superinfected withS. pneumoniae B6.A2G-Mx1 mice were infected with 50 PFU of hvPR/8. 18 hr later, mice received an i.v. injection of 25 μg of 3pRNA. At 4 days after influenza virus infection, mice were challenged with 4.4 × 106 CFU ofS. pneumoniae (strain TIGR4). Mice infected with either influenza orS. pneumoniae but without 3pRNA treatment served as controls (PR/8 only,Streptococcus pneumonia [strept] only, and PR/8 + strept). (A) Experimental setup. (B) Body weight. (C) Survival (log-rank [Mantel-Cox] test: strept versus PR/8 + strept, p = 0.11; strept versus PR/8 + strept + 3pRNA, p = 0.22; PR/8 + strept versus PR/8 + strept + 3pRNA, p = 0.005). (D) Clinical score. Results show mean values of n = 4–6 mice. Error bars represent the SD.
See this image and copyright information in PMC

Comment in

  • Rigging Innate Immunity against the Flu.
    Krieg AM.Krieg AM.Mol Ther. 2017 Sep 6;25(9):1993-1994. doi: 10.1016/j.ymthe.2017.08.008. Epub 2017 Aug 23.Mol Ther. 2017.PMID:28844477Free PMC article.No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., Gubareva L.V., Xu X., Bridges C.B., Uyeki T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009;360:2605–2615. - PubMed
    1. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M., Zaki S.R., Hayden F.G., Hui D.S. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 2010;362:1708–1719. - PubMed
    1. Glezen W.P. Clinical practice. Prevention and treatment of seasonal influenza. N. Engl. J. Med. 2008;359:2579–2585. - PubMed
    1. Hayden F.G., de Jong M.D. Emerging influenza antiviral resistance threats. J. Infect. Dis. 2011;203:6–10. - PMC - PubMed
    1. Ison M.G. Antivirals and resistance: influenza virus. Curr. Opin. Virol. 2011;1:563–573. - PubMed

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp